A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients
Phase of Trial: Phase I/II
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Crenigacestat (Primary) ; Dexamethasone (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 16 Nov 2016 Planned End Date changed from 1 Mar 2018 to 1 Apr 2020.
- 16 Nov 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2019.
- 07 Oct 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.